N/A N=2,105 Randomized Single-blind Screening

The United States Healthy Living Study

Colo-rectal Cancer

Bottom Line

View on ClinicalTrials.gov: NCT03867409 ↗

Enrolled (actual)

2,105

Serious AEs

0.0%

Results posted

May 2025

Primary outcome: Primary: Intention to Talk to Doctor About Colorectal Cancer Screening — 4.14; 4.0; 3.59; 3.48 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: message delivered via virtual technology (Behavioral)
Age: Adult, Older Adult · 50+ yrs
Sex: All
Sponsor: University of Florida
Primary completion: Mar 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Intention to Talk to Doctor About Colorectal Cancer Screening	4.14; 4.0; 3.59; 3.48	—
PRIMARY Intention to Screen for Colorectal Cancer	4.03; 3.91; 3.57; 3.50	—
PRIMARY Intention to Talk About Screening With FIT	4.12; 4.03; 3.65; 3.50	—
PRIMARY Intention to Recommend Intervention (ALEX)	1.35; 1.36; 1.60; 1.66	—
PRIMARY Source Credibility	4.54; 4.42; 4.35; 4.23	—
PRIMARY Argument Strength	4.68; 4.57; 4.48; 4.39	—
PRIMARY Homophily	3.05; 3.04; 2.71; 2.75	—
PRIMARY Usability of App	4.48; 4.33; 4.30; 4.18	—
PRIMARY Perceived Severity	4.47; 4.48; 4.55; 4.51	—
PRIMARY Perceived Susceptibility	3.10; 3.04; 3.35; 3.30	—
PRIMARY Response Efficacy	4.09; 4.14; 4.16; 4.12	—
PRIMARY Self-Efficacy	4.37; 4.32; 4.40; 4.27	—
PRIMARY Perceived Barriers	1.86; 1.92; 1.95; 2.04	—
PRIMARY Perceived Benefits	4.2; 4.18; 4.18; 4.06	—
PRIMARY Comparative Risk Feedback	5.18; 5.19; 5.15; 5.13	—
PRIMARY Cancer Information Overload	2.37; 2.49; 2.83; 2.97	—
PRIMARY Perceived Message Relevance	3.75; 3.66; 3.60; 3.48	—
PRIMARY Trust in Physician	3.86; 3.86; 3.66; 3.65	—
PRIMARY Patient-Provider Communication	4.13; 4.05; 3.86; 3.88	—
PRIMARY Patient General Health	3.09; 3.18; 3.20; 3.17	—
PRIMARY Health Literacy (eHeals)	3.98; 4.02; 3.83; 3.75	—
PRIMARY Interpersonal Distance	3.49; 3.39; 3.37; 3.26	—
PRIMARY Attitudes Towards Fecal Immunochemical Test (FIT) - Sad	1.59; 1.72; 1.67; 1.72	—
PRIMARY Attitudes Towards Fecal Immunochemical Test (FIT) - Worried	2.31; 2.51; 2.4; 2.47	—
PRIMARY Attitudes Towards Fecal Immunochemical Test (FIT) - Relieved	3.53; 3.36; 3.28; 3.05	—
PRIMARY Attitudes Towards Fecal Immunochemical Test (FIT) - Tense	2.50; 2.71; 2.51; 2.63	—
PRIMARY Attitudes Towards Fecal Immunochemical Test (FIT) - Anxious	2.58; 2.82; 2.64; 2.76	—
PRIMARY Attitudes Towards Fecal Immunochemical Test (FIT) - Calm	3.30; 3.18; 3.09; 3.00	—
PRIMARY Attitudes Towards Fecal Immunochemical Test (FIT) - Afraid	2.28; 2.48; 2.32; 2.40	—

Summary

The purpose of this study is to pilot test the efficacy of a patient-centered, tailored message intervention delivered via virtual human technology for increasing colorectal cancer (CRC) screening within guidelines. Although participation is not limited to these groups, the study team is particularly interested in the feasibility of the intervention for reaching racial/ethnic minority and rural patients.

Eligibility Criteria

Inclusion Criteria

reside within the United States but outside of Florida
speak English
are of either black or white racial background.
are out-of-guidelines for colorectal cancer screening (>10 years for colonoscopy, >3 years for Cologuard, > 1 year for fecal immunochemical test)

Exclusion Criteria

does not meet the above criteria

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03867409). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.